Dihydroxyaluminum sodium carbonate
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Dihydroxyaluminum sodium carbonate
- Accession Number
- DB15825
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Dihydroxyaluminum sodium carbonate (DB15825)
- Weight
- Average: 143.993
Monoisotopic: 143.9615309 - Chemical Formula
- CH2AlNaO5
- Synonyms
- Aluminium-natrium-carbonat-dihydroxid
- Aluminum sodium dihydroxide monocarbonate
- Dihydroxo-aluminium-natrium-carbonat
- Dihydroxyaluminum sodium carbonate
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Associated Conditions
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareChenodeoxycholic acid Dihydroxyaluminum sodium carbonate can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Cholic Acid Dihydroxyaluminum sodium carbonate can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Dehydrocholic acid Dihydroxyaluminum sodium carbonate can cause a decrease in the absorption of Dehydrocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Deoxycholic acid Dihydroxyaluminum sodium carbonate can cause a decrease in the absorption of Deoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Dolutegravir The serum concentration of Dolutegravir can be decreased when it is combined with Dihydroxyaluminum sodium carbonate. Halofantrine Dihydroxyaluminum sodium carbonate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. Obeticholic acid Dihydroxyaluminum sodium carbonate can cause a decrease in the absorption of Obeticholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Ox bile extract The serum concentration of Ox bile extract can be decreased when it is combined with Dihydroxyaluminum sodium carbonate. Phenytoin Dihydroxyaluminum sodium carbonate can cause a decrease in the absorption of Phenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy. Taurocholic acid Dihydroxyaluminum sodium carbonate can cause a decrease in the absorption of Taurocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- International/Other Brands
- Daxaids / Noacid / Rolaids
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image ทิมมี่ Tablet 334 mg Oral บริษัท บี.เอ็ล.ฮั้ว จำกัด จำกัด 1987-02-18 Not applicable Thailand 
ทิมมี่ Tablet 334 mg Oral บริษัท บี.เอ็ล.ฮั้ว จำกัด จำกัด 1987-02-18 Not applicable Thailand
Categories
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- 84H8Z9550J
- CAS number
- 16482-55-6
- InChI Key
- SEIGJEJVIMIXIU-UHFFFAOYSA-J
- InChI
- InChI=1S/CH2O3.Al.Na.2H2O/c2-1(3)4;;;;/h(H2,2,3,4);;;2*1H2/q;+3;+1;;/p-4
- IUPAC Name
- sodium dihydroxyalumanylium carbonate
- SMILES
- [Na+].O[Al+]O.[O-]C([O-])=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 7969582
- 23163
- ChEMBL
- CHEMBL3707202
- Wikipedia
- Carbaldrate
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral 340 mg Tablet Oral 334 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 269.0 mg/mL ALOGPS logP -0.71 ALOGPS logP 0.25 ChemAxon logS 0.27 ALOGPS pKa (Strongest Acidic) 3.5 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 63.19 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 31.17 m3·mol-1 ChemAxon Polarizability 3.52 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created on September 11, 2020 17:56 / Updated on February 21, 2021 18:55